{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:55Z","timestamp":1781636095263,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015389","name":"Suomen Onkologiayhdistys","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The incidence of breast cancer has increased, and many more cases are being detected with favorable tumor characteristics and in older age. The guidelines for treating early breast cancer have evolved as new treatments have become available. Our aim was to study the extent to which the guidelines reflect the real-world setting and whether guideline non-adherence is more frequent in some patient groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from 803 women aged 40\u201384 years diagnosed with early breast cancer between 1992 and 2011 were retrieved from the clinical patient files and the Finnish Cancer Registry. To study adherence to existing national guidelines, undertreatment and overtreatment with respect to the guidelines were considered non-adherence, and adherence status was analyzed using multivariable regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the study period, the proportion of patients with guideline-based indications for systemic adjuvant treatment increased from 43.8% to 98.9%, while adherence to the guidelines decreased from 82.2% to 70.1%. Undertreatment was more frequent in the later years of the study (odds ratio [OR] 2.77; confidence interval [CI] 95% 1.67\u20134.59) compared to the beginning of the study, and more frequent among patients 70 years or older (OR 1.86; CI 95% 1.22\u20132.84) compared to patients 50\u201369 years of age. Undertreatment was more common in node-negative (T2-4N0) cases than in node-positive cases (OR 2.14; CI 95% 1.16\u20133.96).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>As treatment indications expand, it should be acknowledged that the results of clinical trials can only be applied to a portion of real-world patients, resulting in a decrease in guideline adherence. This dynamic should be considered in future guidelines and clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15731-x","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:53:49Z","timestamp":1771203229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nonadherence to changing guidelines in early breast cancer over two decades"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9866-2496","authenticated-orcid":false,"given":"Annikki","family":"Aromaa-H\u00e4yh\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8127-8087","authenticated-orcid":false,"given":"Nea","family":"Malila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesa","family":"Kataja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"15731_CR1","unstructured":"Finnish Cancer Registry. https:\/\/cancerregistry.fi\/statistics\/. Accessed Nov 30 2024."},{"key":"15731_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/s0140-6736(95)90223-6","volume":"345","author":"M Hakama","year":"1995","unstructured":"Hakama M, Holli K, Isola J, et al. Aggressiveness of screen-detected breast cancers. Lancet. 1995;345:221\u20134. https:\/\/doi.org\/10.1016\/s0140-6736(95)90223-6.","journal-title":"Lancet"},{"key":"15731_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/1471-2407-9-335","volume":"9","author":"M Nothacker","year":"2009","unstructured":"Nothacker M, Duda V, Hahn M, et al. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue: a systematic review (Structured abstract). BMC Cancer. 2009;9:335.","journal-title":"BMC Cancer"},{"key":"15731_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3109\/0284186X.2016.1171392","volume":"55","author":"S Heikkinen","year":"2016","unstructured":"Heikkinen S, Miettinen J, Koskenvuo M, et al. Proportion of women with self-reported opportunistic mammography before organized screening. Acta Oncol. 2016;55:865\u20139. https:\/\/doi.org\/10.3109\/0284186X.2016.1171392.","journal-title":"Acta Oncol"},{"key":"15731_CR5","doi-asserted-by":"publisher","unstructured":"Anderson KN, Schwab RB, Martinez ME. (2014) Reproductive risk factors and breast cancer subtypes: a review of the literature.\\. Breast Cancer ResTreat 144\\:1\u201310\\. https:\/\/doi.org\/10.1007\/s10549-014-2852-7","DOI":"10.1007\/s10549-014-2852-7"},{"key":"15731_CR6","unstructured":"Suomen rintasy\u00f6p\u00e4ryhm\u00e4 ry. (1994) Rintasy\u00f6v\u00e4n valtakunnallinen diagnostiikka- ja hoitosuositus."},{"key":"15731_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","author":"S Loibl","year":"2023","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up(\u2020). Ann Oncol S. 2023. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016. 0923-7534(23)05104\u20139.","journal-title":"Ann Oncol S"},{"key":"15731_CR8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/aje\/kwaa236","volume":"190","author":"T Tanskanen","year":"2021","unstructured":"Tanskanen T, Sepp\u00e4 KJM, Virtanen A, et al. Cancer incidence and mortality in the oldest old: A nationwide study in Finland. Am J Epidemiol. 2021;190:836\u201342. https:\/\/doi.org\/10.1093\/aje\/kwaa236.","journal-title":"Am J Epidemiol"},{"key":"15731_CR9","unstructured":"GLOBOCAN. 2020. https:\/\/www.uicc.org\/news\/globocan-2020-new-global-cancer-data. Accessed Nov 30 2024."},{"key":"15731_CR10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1080\/0284186X.2018.1479073","volume":"57","author":"A Aromaa-H\u00e4yh\u00e4","year":"2018","unstructured":"Aromaa-H\u00e4yh\u00e4 A, Auvinen P, Sarkeala T, et al. Improved diagnostics and change of tumour characteristics in breast cancer: a retrospective study over two decades. Acta Oncol. 2018;57:1331\u20138. https:\/\/doi.org\/10.1080\/0284186X.2018.1479073.","journal-title":"Acta Oncol"},{"key":"15731_CR11","unstructured":"AJCC Cancer Staging System Products. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/american-joint-committee-on-cancer\/cancer-staging-systems\/cancer-staging-system-products\/. Accessed Nov 30 2024."},{"key":"15731_CR12","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. AnnOncol. 2011;22:1736\u201347. https:\/\/doi.org\/10.1093\/annonc\/mdr304.","journal-title":"AnnOncol"},{"key":"15731_CR13","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","volume":"27","author":"H Joensuu","year":"2009","unstructured":"Joensuu H, Bono P, Kataja V, et al. Fluorouracil, Epirubicin, and cyclophosphamide with either docetaxel or Vinorelbine, with or without Trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. JCO. 2009;27:5685\u201392. https:\/\/doi.org\/10.1200\/JCO.2008.21.4577.","journal-title":"JCO"},{"key":"15731_CR14","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEnglJMed. 2005;353:1659\u201372.","journal-title":"NEnglJMed"},{"key":"15731_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10549-016-3940-7","volume":"159","author":"AMF Verschoor","year":"2016","unstructured":"Verschoor AMF, Kuijer A, Verloop J, et al. Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level. Breast Cancer Res Treat. 2016;159:357\u201365. https:\/\/doi.org\/10.1007\/s10549-016-3940-7.","journal-title":"Breast Cancer Res Treat"},{"key":"15731_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1524-4741.2011.01074.x","volume":"17","author":"I Weggelaar","year":"2011","unstructured":"Weggelaar I, Aben KK, Warl\u00e9 MC, et al. Declined guideline adherence in older breast cancer patients: a population-based study in the Netherlands. Breast J. 2011;17:239\u201345. https:\/\/doi.org\/10.1111\/j.1524-4741.2011.01074.x.","journal-title":"Breast J"},{"key":"15731_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10549-020-05657-8","volume":"181","author":"E Ni\u00f1o de Guzm\u00e1n","year":"2020","unstructured":"Ni\u00f1o de Guzm\u00e1n E, Song Y, Alonso-Coello P, et al. Healthcare providers\u2019 adherence to breast cancer guidelines in europe: a systematic literature review. Breast Cancer Res Treat. 2020;181:499\u2013518. https:\/\/doi.org\/10.1007\/s10549-020-05657-8.","journal-title":"Breast Cancer Res Treat"},{"key":"15731_CR18","unstructured":"THL\u00b4s Morbidity Index. https:\/\/thl.fi\/en\/statistics-and-data\/data-and-services\/quality-and-statistical-principles\/quality-descriptions\/thl-morbidity-index."},{"key":"15731_CR19","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","volume":"33","author":"M Di Maio","year":"2022","unstructured":"Di Maio M, Basch E, Denis F, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline. Ann Oncol. 2022;33:878\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2022.04.007.","journal-title":"Ann Oncol"},{"key":"15731_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jama.2018.18085","volume":"321","author":"F Denis","year":"2019","unstructured":"Denis F, Basch E, Septans A-L, et al. Two-Year survival comparing Web-Based symptom monitoring vs routine surveillance following treatment for lung cancer. JAMA. 2019;321:306\u20137. https:\/\/doi.org\/10.1001\/jama.2018.18085.","journal-title":"JAMA"},{"key":"15731_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing Patient-Reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318:197\u20138. https:\/\/doi.org\/10.1001\/jama.2017.7156.","journal-title":"JAMA"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15731-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15731-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15731-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:17:51Z","timestamp":1781633871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15731-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15731"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15731-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Permission for this study was provided by the Finnish National Institute for Health and Welfare (THL\/457\/5.05.00\/2012) and the Ethics Committee of the University of Eastern Finland (31\/\/2013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Concent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"530"}}